BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34676172)

  • 1. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation.
    Zhao W; Jiang L; Fang T; Fang F; Liu Y; Zhao Y; You Y; Zhou H; Su X; Wang J; Liu S; Chen Y; Wan J; Huang X
    Front Oncol; 2021; 11():747282. PubMed ID: 34676172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
    Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
    Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
    Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
    Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
    Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
    Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
    Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
    Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
    Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
    Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
    Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
    J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
    Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
    Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
    Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
    Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
    Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
    Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
    Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented Concentration of Isopentyl-Deoxynyboquinone in Tumors Selectively Kills NAD(P)H Quinone Oxidoreductase 1-Positive Cancer Cells through Programmed Necrotic and Apoptotic Mechanisms.
    Wang J; Su X; Jiang L; Boudreau MW; Chatkewitz LE; Kilgore JA; Zahid KR; Williams NS; Chen Y; Liu S; Hergenrother PJ; Huang X
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
    Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
    Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
    Beg MS; Huang X; Silvers MA; Gerber DE; Bolluyt J; Sarode V; Fattah F; Deberardinis RJ; Merritt ME; Xie XJ; Leff R; Laheru D; Boothman DA
    J Surg Oncol; 2017 Jul; 116(1):83-88. PubMed ID: 28346693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Base Excision Repair in Cancer: NQO1-Bioactivatable Drugs Improve Tumor Selectivity and Reduce Treatment Toxicity Through Radiosensitization of Human Cancer.
    Starcher CL; Pay SL; Singh N; Yeh IJ; Bhandare SB; Su X; Huang X; Bey EA; Motea EA; Boothman DA
    Front Oncol; 2020; 10():1575. PubMed ID: 32974194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers.
    Tumbath S; Jiang L; Li X; Zhang T; Zahid KR; Zhao Y; Zhou H; Yin Z; Lu T; Jiang S; Chen Y; Chen X; Fu YX; Huang X
    Oncoimmunology; 2024; 13(1):2363000. PubMed ID: 38846085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IP-DNQ induces mitochondrial dysfunction and G2/M phase cell cycle arrest to selectively kill NQO1-positive pancreatic cancer cells.
    Jiang L; Liu Y; Tumbath S; Boudreau MW; Chatkewitz LE; Wang J; Su X; Zahid KR; Li K; Chen Y; Yang K; Hergenrother PJ; Huang X
    Antioxid Redox Signal; 2023 Nov; ():. PubMed ID: 37950707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
    Park HJ; Choi EK; Choi J; Ahn KJ; Kim EJ; Ji IM; Kook YH; Ahn SD; Williams B; Griffin R; Boothman DA; Lee CK; Song CW
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8866-71. PubMed ID: 16361576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma.
    Shimokawa M; Yoshizumi T; Itoh S; Iseda N; Sakata K; Yugawa K; Toshima T; Harada N; Ikegami T; Mori M
    Cancer Sci; 2020 Apr; 111(4):1228-1240. PubMed ID: 31968140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.